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    ABSTRACT  Objectives    To compare the effects of a combined oral contraceptive (COC) containing 
nomegestrol acetate and 17  β  -oestradiol (NOMAC/E2) on haemostasis, lipids, carbohydrate 
metabolism, C-reactive protein (CRP) and sex hormone-binding globulin (SHBG) with 
those of a COC containing levonorgestrel and ethinylestradiol (LNG/EE).     
     Methods    In a randomised, open-label study, 121 healthy women, 18  –  50 years of age, were 
randomly assigned to receive NOMAC/E2 (2.5 mg/1.5 mg) in a 24/4-day regimen (  n       60) 
or LNG/EE (150   μ  g/30   μ  g) in a 21/7-day regimen (  n        61) for six cycles. The primary 
outcome was the change from baseline to cycle 6 for all indices.     
     Results    All parameters were similar at baseline between the two groups. Over six cycles, 
NOMAC/E2 had less effect on most haemostatic indices than LNG/EE. Lipids were essen-
tially unchanged with NOMAC/E2, whereas with LNG/EE high-density lipoprotein cho-
lesterol decreased and low-density lipoprotein cholesterol and triglycerides slightly increased. 
NOMAC/E2 induced negligible changes in glucose and insulin parameters, in contrast to 
LNG/EE. A much smaller increase in CRP was observed with NOMAC/E2 than with 
LNG/EE. NOMAC/E2 was associated with a greater increase in SHBG.     
     Conclusions    The monophasic COC NOMAC/E2 had less inﬂ   uence on haemostasis, 
lipids and carbohydrate metabolism than the COC LNG/EE.   
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      INTRODUCTION   
  Since their introduction 50 years ago, combined oral 
contraceptives (COCs) have become the most fre-
quently used method of reversible contraception 
worldwide  1  . Over the past few decades, many advances 
have been achieved in COCs, including a reduction 
in the dose of the oestrogenic component ethinylestra-
diol (EE) and the introduction of more selective pro-
gestogens. This has resulted in improved tolerability  2   
and a more favourable cardiovascular risk proﬁ  le  3,4  . 
The use of oestrogens and progestogens that are iden-
tical to or show greater resemblance with endogenous 
hormones represents the most recent advancement in 
COC development. 
  While the EE content in COCs is correlated with 
increased venous thromboembolism (VTE) risk, the 
inﬂ  uence of the progestogen component on VTE risk 
is controversial  5  . Although it has been suggested that 
some newer progestogens are associated with greater 
VTE risk  6,7  , the methodologies used in these studies 
have come into question  8,9  . Another study looked at 
confounders (weight, body mass index, smoking status, 
age, etc.) and found that COCs containing levonorg-
estrel (LNG) or norgestimate had similar VTE risk 
proﬁ  les compared with COCs containing gestodene 
or desogestrel  10  . Results from a post-marketing sur-
veillance study (142,475 woman-years) that monitored 
cardiovascular outcomes among COC users (including 
those containing drospirenone [DRSP] or LNG) in 
Europe suggested that VTE risk was similar, indepen-
dent of progestogen type  11  . Prescriber bias may also 
contribute to higher VTE rates, especially in smokers 
who may be more likely to receive prescriptions for 
COCs that contain newer progestogens  5  . 
  For several decades, researchers have been trying to 
incorporate the natural hormone 17  β  -oestradiol (E2), 
which is identical to the endogenous oestrogen, into 
COCs. Although many early formulations that con-
tained E2 were associated with poor cycle control, 
which limited E2  ’ s clinical usefulness, initiatives to 
replace synthetic oestrogen with physiological hor-
mone continued. It is still hypothesised that the use of 
E2 in combination with a suitable progestogen could 
further improve tolerability and minimise the deleteri-
ous effects of EE on hepatic metabolism  12  . 
  Recently, a monophasic COC containing nomege-
strol acetate (NOMAC) in combination with E2 has 
been developed. NOMAC is a progestogen structurally 
similar to progesterone; it is devoid of oestrogenic, 
androgenic, glucocorticoid, and mineralocorticoid 
activity but displays an antioestrogenic activity on the 
endometrium and a moderate antiandrogenic activ-
ity  13  . Due to the enhanced selectivity proﬁ  le  of 
NOMAC, this COC may provide acceptable cycle 
control with putative neutral effects on cardiovascular 
or metabolic risks  14  . 
  The COC containing NOMAC/E2 (2.5 mg/1.5 
mg) administered in a 24/4 (active/placebo)-day regi-
men provides effective suppression of ovarian activity 
and acceptable cycle control in women of childbearing 
age  15,16  . NOMAC/E2 has also demonstrated suppressive 
effects on the ovaries, cervical mucus and endome-
trium that are at least as strong as those of a comparator 
COC containing DRSP and EE  15  . 
  The current study was performed to assess the effects 
of NOMAC/E2 on haemostasis, lipids, carbohydrate 
metabolism, C-reactive protein (CRP), and sex hor-
mone-binding globulin (SHBG). The inﬂ  uence  of 
NOMAC/E2 on surrogate markers of adrenal and thy-
roid function, androgens, and androgen precursors was also 
evaluated, but will be reported separately  17  . LNG/EE 
(150   μ  g/30   μ  g) was used as a comparator based on 
regulatory guidance for safety evaluation of new COCs  18  .    
    METHODS   
  The study was a randomised, open-label, comparative, 
parallel-design study conducted in ﬁ  ve study centres 
in Finland. Advertisements were used to recruit 
women from the regions surrounding the study cen-
tres (Kuopio, Tampere, Turku, Espoo, and Oulu). 
Throughout the trial, study volunteers were compen-
sated for their time, travel costs, and inconvenience 
associated with study visits. 
  The study complied with the ethical principles of the 
Declaration of Helsinki and the International Conference 
on Harmonisation (ICH) guideline for Good Clinical 
Practice. An independent Ethics Committee reviewed 
and approved the study protocol (NCT00511355) before 
the start of the study. All participants in the study pro-
vided written informed consent.   
  Subjects 
  Healthy, sexually active women aged 18  –  50 years with 
a body mass index between 17  –  29 kg/m  2   were eligible Effects of NOMAC/E2 on haemostasis and lipids    Ågren et al.
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  Laboratory measurements 
  All laboratory examinations were performed by the 
Bio Analytical Research Corporation (Ghent, 
Belgium).   
  Haemostasis   
  Thrombin turnover/ﬁ   brinolysis indices  .   Enzyme-linked 
immunosorbent assays (ELISAs) (Enzygnost  ∗   F 1       2 
[monoclonal] assay, Dade Behring Marburg GmbH, 
Marburg, Germany) were performed to quantify pro-
thrombin fragment 1        2. D-dimer was measured by 
the immunoturbidimetric assay STA    ®    Liatest    ®    D-DI 
on an STA Analyser (Diagnostica Stago, Asi  è  res sur 
Seine, France).     
  Anticoagulatory indices  .   A thrombin generation test 
using the ﬂ  uorescence-based Thrombinoscope tech-
nique (Thrombinoscope BV, Maastricht, The Neth-
erlands) was performed to calculate the endogenous 
thrombin potential (ETP)-based activated protein C 
(APC) sensitivity ratio. The activated partial throm-
boplastin time (aPTT)-based APC sensitivity ratio 
was determined using the Coatest    ®     APC  ™   Resis-
tance test (Chromogenix   –   Instrumentation Labora-
tory SpA, Milan, Italy) with the STA Compact    ®    
(Diagnostica Stago). The activity of antithrombin III 
(ATIII) was measured by means of the colorimetric 
STA STAchrom ATIII assay using bovine thrombin 
in an STA Compact (Diagnostica Stago) and protein 
C activity by means of the enzymatic chromogenic 
STAchrom Protein C assay on an STA Analyser 
(Diagnostica Stago). The immunoturbidimetric assay 
STA Liatest Free Protein S was used on an STA 
Analyser (Diagnostica Stago) to measure free protein 
S antigen. Total protein S antigen was detected using 
the ELISA Asserachrom    ®     Total Protein S kit (Diag-
nostica Stago).     
  Procoagulatory indices  .   Factor II activity, factor VII coag-
ulant activity (factor VIIc) and activated factor VII 
(factor VIIa) were measured using the commercial 
clotting assays/reagents STA-Deﬁ  cient II, STA-Deﬁ  -
cient VII, STAclot VIIa-RTF, STA-Neoplastine 
CI      and the automated analyser STA Compact 
(Diagnostica Stago). Factor VIII activity was deter-
mined by measuring factor dilution activity using the 
STA Analyser (Diagnostica Stago).       
if they had no contraindications for the use of con-
traceptive steroids and had not taken any other hor-
monal treatment (except contraceptives) during the 
two months preceding screening. Other exclusion 
criteria included an abnormal cervical smear; a clini-
cally relevant abnormal laboratory ﬁ  nding; breastfeeding; 
and use of liver-enzyme-inducing drugs, investiga-
tional drugs or pharmacological agents affecting the 
haemostatic system (e.g., vitamin K, nonsteroidal anti-
inﬂ  ammatory drugs, including aspirin).     
  Study design 
  The study consisted of one pre-treatment cycle (cycle 
0), six 28-day treatment cycles (cycles 1  –  6), and a 
post-treatment follow-up. At the screening visit, sub-
jects were evaluated to determine their eligibility and 
collect general baseline data. They were instructed to 
discontinue the use of hormonal contraceptives, if 
applicable, and to use condoms whenever necessary. 
The pre-treatment cycle visit took place in the sec-
ond half of the ﬁ  rst spontaneous menstrual cycle after 
the screening visit. During the pre-treatment cycle 
visit, blood was taken in a fasted state during the 
morning for baseline assessment of metabolic indices 
and an oral glucose tolerance test (OGTT) was 
performed. 
  Eligible women were randomised in a 1:1 ratio to 
receive the investigational COC containing 2.5 mg 
NOMAC and 1.5 mg E2   or   the comparator COC 
containing 150   μ  g LNG and 30   μ  g EE. Randomisa-
tion was performed using blocks with randomly per-
muted block sizes and an interactive voice response 
system. Women were stratiﬁ  ed by age class (i.e., 18  –  35 
years and 36  –  50 years). For six consecutive 28-day 
cycles, the women took one tablet of the study medi-
cation orally at approximately the same time each day 
from day 1 to day 28. The NOMAC/E2 regimen 
comprised 24 days of active hormone pills followed 
by four days of placebo pills; the LNG/EE regimen 
comprised 21 days of active hormone pills followed 
by seven days of placebo pills. Blood collection for 
metabolic assessments and an OGTT were repeated 
between day 15 and day 21 of treatment cycles 3 and 
6 when participants returned for clinic visits in a fasted 
state. A ﬁ  nal visit was scheduled between 8 and 14 days 
after the last tablet was taken in cycle 6 or after early 
discontinuation of treatment for the gathering of gen-
eral follow-up data.     Effects of NOMAC/E2 on haemostasis and lipids    Ågren et al.
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  Lipids 
  Serum levels of total cholesterol and triglycerides 
were determined enzymatically using cholesterol oxi-
dase-phenol/aminophenazone (CHOD-PAP) and 
glycerol-3-phosphate oxidase (GPO)-PAP methods, 
respectively, on a Modular P Analyser (Roche Diag-
nostics GmbH, Mannheim, Germany). High-density 
lipoprotein cholesterol (HDL-C) values were mea-
sured using modiﬁ   ed enzymatic procedures on a 
Modular P system; low-density lipoprotein choles-
terol (LDL-C) values were estimated by the Friede-
wald equation (i.e., total cholesterol minus HDL-C 
minus very low-density lipoprotein cholesterol esti-
mated as triglyceride level divided by ﬁ  ve)  19  . Lipo-
protein (a) and apolipoprotein A1 and B levels were 
assessed by immunoturbidimetry on a Modular P sys-
tem (Roche Diagnostics).     
  Carbohydrate metabolism indices 
  For the OGTT, glucose and insulin levels were mea-
sured before (t        0) and at 30, 60, 90, 120 and 180 
minutes after drinking a glucose solution (75 g/100 ml). 
Serum glucose levels were measured according to the 
hexokinase ultraviolet method on a Modular P sys-
tem; serum insulin levels were estimated by chemilu-
minescence (CLIA test) using the automated immu-
nochemiluminescence analyser Immulite    ®    (DPC 
Biermann, Bad Nauheim, Germany). Ion-exchange 
high-performance liquid chromatography was per-
formed using the automated analyser HA-8160 (A. 
Menarini Diagnostics S.r.l., Firenze, Italy) for the 
determination of haemoglobin type A  1c   (HbA  1c  ).     
  CRP and SHBG 
  Serum levels of CRP were obtained with the immu-
nochemiluminescence analyser Immulite    ®    (DPC 
Biermann, Bad Nauheim, Germany). The electro-
chemiluminescence immunoassay ECLIA (Roche 
Diagnostics) was used to measure serum levels of 
SHBG.       
  Statistical analysis 
  The trial was set up to conﬁ  rm the expected differ-
ences in changes from baseline between the treat-
ment groups in several metabolic indices, especially 
prothrombin fragment 1    2, D-dimer and ATIII. 
In previous trials (unpublished data), standardised 
effect sizes (i.e., differences between the treatment 
groups in changes from baseline divided by the com-
mon standard deviation) were found to be in the 
range of approximately 0.6  –  1.0, depending on the 
parameter and the variability range. Conservatively 
assuming a standardised effect size of approximately 
0.6 as a difference worthwhile to detect, a sample size 
of 42 evaluable subjects per treatment group was 
needed using a two-sided statistical test with 80% 
power and a signiﬁ  cance level of 5%. Compensating 
for up to 20% premature discontinuations from treat-
ment and accounting for a potential power loss due 
to the non-parametric analysis, in total 60 subjects 
were to be randomised per treatment group. 
  Analyses of all metabolic indices were performed 
for all randomised subjects who took at least one 
dose of study medication. For all parameters, median 
values and interquartile ranges at baseline (deﬁ  ned 
as the last measurement before administration of the 
ﬁ  rst study medication) and treatment cycles 3 and 
6 are presented, as well as changes from baseline to 
cycle 6 (primary outcome). Interquartile ranges 
were preferred over standard deviations in order to 
limit the inﬂ  uence of outliers on the variability esti-
mates. If a value less than the lower limit of quan-
tiﬁ   cation (LLOQ) was observed for a metabolic 
variable, a value of 0.5        LLOQ for the respective 
laboratory test was imputed. If a value above the 
upper limit of quantiﬁ  cation (ULOQ) was reported, 
a value equal to the ULOQ of the respective labora-
tory test was used. 
  Glucose and insulin responses during the OGTT 
were evaluated as the area under the curve over three 
hours (AUC  3  ), which were calculated according to 
the trapezoidal rule. A correction factor was used if 
the last blood sample was not drawn at the exact time 
of 180 minutes after glucose administration. Based on 
the calculated AUC  3  , the incremental AUC  3   was 
deﬁ  ned as the difference between the AUC  3   and the 
concentration before OGTT (fasting concentration) 
multiplied by three hours. 
  All statistical analyses of metabolic parameters used 
two-sided tests performed at the 5% error level. Each 
parameter was analysed using a stratiﬁ  ed Wilcoxon 
rank sum test (Cochran-Mantel-Haenszel test) 
adjusted for age class, applied on the changes from 
baseline to cycle 6. No correction for multiplicity was 
applied.       Effects of NOMAC/E2 on haemostasis and lipids    Ågren et al.
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  Haemostasis 
  Prothrombin fragments 1   2 essentially did not change 
in the NOMAC/E2 group, whereas a small increase 
in the LNG/EE group was observed (  p       0.085; Table 
2; Figure 2). Although D-dimer was nearly unchanged 
in both groups, these results are inconclusive because 
more than 50% of the values were below the limit of 
detection. 
  The ETP-based APC sensitivity ratio increased by 
a statistically signiﬁ  cant margin from baseline to cycle 
6 in both groups; however, the change was much 
greater with LNG/EE than with NOMAC/E2 
(  p        0.001; Table 2; Figure 2). The aPTT-based sensi-
tivity ratio was nearly unchanged in both groups. Small 
changes from baseline were observed in the anticoagu-
latory factors ATIII, protein C, and free and total pro-
tein S in both treatment groups (Table 2), but the 
between-group differences for these parameters were 
found to be statistically signiﬁ  cant (  p       0.01; Table  2) 
except for free protein S. 
  NOMAC/E2 and LNG/EE induced minimal 
changes from baseline in procoagulatory factors II, 
VIIa and VIII (Table 2). For factor VIIc, a minimal 
change from baseline was observed in the NOMAC/
E2 group, whereas a decrease was observed in the 
LNG/EE group (  p       0.001; Table  2).      
    RESULTS   
  A total of 121 women were randomised to receive 
either NOMAC/E2 or LNG/EE (Figure 1). All 60 
women in the NOMAC/E2 group received treat-
ment; three of the 61 women in the LNG/EE group 
did not receive treatment because of a pre-treatment 
adverse event (AE) (  ‘  acne  ’  ), withdrawn consent or 
other personal reasons (found a new job). Seven 
women (11.7%) in the NOMAC/E2 group and six 
women (10.3%) in the LNG/EE group discontinued 
the treatment prematurely. Of these 13 discontinu-
ers, eight women (four in each group) discontinued 
due to an AE, one due to pregnancy wish, one 
moved to another city, and three women were lost 
to follow-up. Overall tablet intake compliance was 
high in both treatment groups: 93.1% and 87.7% of 
women in the NOMAC/E2 and LNG/EE groups, 
respectively, took the daily tablet on at least 95% of 
treatment days.  
  The demographic and clinical characteristics were 
similar between the two treatment groups at base-
line (Table 1), with the exception of smoking preva-
lence, which was higher among women in the 
NOMAC/E2 group. Baseline values for all meta-
bolic indices in the two treatment groups were also 
similar (Tables 2  –  4).    
     
Figure 1   Disposition of subjects. NOMAC/E2, nomegestrol acetate/17  β  -oestradiol; LNG/EE, levonorgestrel/ethinylestradiol.   Effects of NOMAC/E2 on haemostasis and lipids    Ågren et al.
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  Lipids 
  No clinically relevant changes were seen in total 
cholesterol, HDL-C, LDL-C, or total triglycerides 
among women receiving NOMAC/E2 during six 
treatment cycles (Table 3; Figure 2). LNG/EE treat-
ment did not change total cholesterol either, but it 
decreased HDL-C, increased LDL-C, and increased 
total triglycerides. The decrease from baseline in 
HDL-C and the increase from baseline in LDL-C 
and total triglycerides observed in the LNG/EE 
group were statistically signiﬁ  cantly different from 
changes observed in the NOMAC/E2 group 
(  p        0.05; Table 3). No changes in lipoprotein (a) 
were observed in the NOMAC/E2 group, and small 
changes were observed in the LNG/EE group, the 
difference being statistically signiﬁ  cant (  p       0.001). 
Women in the NOMAC/E2 group had a signiﬁ  -
cantly greater increase from baseline in apolipopro-
tein A1 ( p       0.006) and a signiﬁ  cantly smaller increase 
in apolipoprotein B (  p        0.001) than those in the 
LNG/EE group.     
  Carbohydrate metabolism 
  Over six cycles of treatment, women receiving 
NOMAC/E2 had negligible changes from baseline in 
the AUC  3   and incremental AUC  3   for both glucose 
and insulin (Table 4). In the LNG/EE group, increases 
from baseline were observed for all four parameters. 
The differences between treatment groups were sta-
tistically signiﬁ  cant for all of these indices (  p        0.002; 
Table 4). No changes in HbA  1c   were observed in 
either group.      
      Table 1    Subject characteristics at screening.   
  NOMAC/E2 
      (n     60) 
  LNG/EE 
      (n     58) 
  Total 
    (  n     118) 
Age (years), mean (SD) 28.2 (8.2) 29.1 (7 .8) 28.7 (8.0)
Race,   n   (%)
Black 1 (1.7) 0 1 (0.8)
White 59 (98.3) 58 (100.0) 117 (99.2)
Weight (kg), mean (SD) 62.8 (9.7) 61.7 (9.0) 62.3 (9.3)
BMI (kg/m  2  ), mean (SD) 23.0 (2.9) 22.3 (2.5) 22.7 (2.7)
Nulligravida,   n   (%) 35 (58.3) 34 (58.6) 69 (58.5)
Parity  *  ,   n   (%)
NA (0 without pregnancy) 35 34 69
0 (with pregnancy) 4 (16.0) 3 (12.5) 7 (14.3)
1 7 (28.0) 6 (25.0) 13 (26.5)
      2 14 (56.0) 15 (62.5) 29 (59.2)
Last contraceptive method used within 
three months prior to screening  *    *  ,   n   (%)
None 1 (1.7) 4 (6.9) 5 (4.2)
Combined oral contraceptive 19 (31.7) 22 (37 .9) 41 (34.7)
Progestogen-only-pill 3 (5.0) 1 (1.7) 4 (3.4)
IUD (hormonal) 5 (8.3) 1 (1.7) 6 (5.1)
IUD (non-hormonal) 1 (1.7) 2 (3.4) 3 (2.5)
Vaginal ring or transdermal patch 5 (8.3) 7 (12.1) 12 (10.2)
Foam, condom, suppositories, diaphragm 26 (43.3) 21 (36.2) 47 (39.8)
Smoking status
Smokers,   n   (%) 14 (23.3) 7 (12.1) 21 (17 .8)
Non-smokers,   n   (%) 46 (76.7) 51 (87 .9) 97 (82.2)
  NOMAC/E2, nomegestrol acetate/17  β  -oestradiol; LNG/EE, levonorgestrel/ethinylestradiol; SD, standard deviation; 
BMI, body mass index; NA, not applicable; IUD, intrauterine device. 
        *  Gestational age       28  weeks;    
    *    *  Single most important contraceptive method.         Effects of NOMAC/E2 on haemostasis and lipids    Ågren et al.
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      Table 2    Comparison of the effects of nomegestrol acetate/17  β  -oestradiol (NOMAC/E2) and levonorgestrel/
ethinylestradiol (LNG/EE) on thrombin turnover/ﬁ  brinolysis indices, anticoagulatory factors, and procoagulatory factors 
(medians [interquartile ranges])    .
  Thrombin turnover/ﬁ  brinolysis indices 
  Treatment    Baseline   Cycle 3    Cycle 6 
  Change from 
baseline to cycle 6 
  % change from 
baseline to cycle 6    p-value  *   
  Prothrombin fragments 1       2  (nmol/l) 
NOMAC/E2 0.15 (0.07) 0.15 (0.08) 0.14 (0.10)        0.00  (0.06)      1.7  (46.0) 0.085
LNG/EE 0.17 (0.10) 0.21 (0.12) 0.21 (0.12) 0.02 (0.10) 13.5 (59.6)
  D-dimer (mg/l FEU) 
NOMAC/E2 0.11 (0.19) 0.11 (0.16) 0.11 (0.12) 0.00 (0.00) 0.0 (0.0)     †  
LNG/EE 0.11 (0.15) 0.22 (0.26) 0.11 (0.22) 0.00 (0.17) 0.0 (68.0)
  Anticoagulatory factors 
  ETP-based APC sensitivity ratio 
NOMAC/E2 0.70 (0.40) 1.10 (0.60) 1.10 (0.40) 0.40 (0.60) 60.0 (80.0)        0.001
LNG/EE 0.70 (0.60) 2.20 (1.00) 1.90 (1.25) 1.20 (1.00) 146.4 (160.0)
  aPTT-based APC sensitivity ratio 
NOMAC/E2 1.00 (0.20) 0.98 (0.17) 1.05 (0.16) 0.03 (0.17) 3.3 (16.4) 0.97
LNG/EE 0.99 (0.14) 0.99 (0.13) 1.02 (0.13) 0.02 (0.15) 2.0 (14.9)
  Antithrombin III (%) 
NOMAC/E2 99.5 (13.5) 100.0 (15.0) 103.0 (12.0) 4.0 (14.0) 3.9 (13.4) 0.004
LNG/EE 99.0 (15.0) 95.5 (10.0) 95.5 (16.5)        3.5  (14.0)      3.6  (14.1)
  Protein C (U/l) 
NOMAC/E2 105.5 (17 .5) 101.0 (19.0) 104.0 (29.0)        3.0  (19.0)      3.1  (18.3) 0.002
LNG/EE 102.5 (25.0) 111.0 (24.0) 113.0 (25.5) 8.5 (20.0) 8.2 (20.2)
  Free protein S (%) 
NOMAC/E2 84.0 (20.5) 96.0 (22.0) 99.0 (33.0) 11.0 (18.0) 13.3 (21.0) 0.97
LNG/EE 85.0 (18.0) 93.5 (22.0) 102.0 (24.5) 11.5 (21.5) 11.9 (25.9)
  Total protein S (%) 
NOMAC/E2 79.0 (13.5) 85.0 (17 .0) 83.0 (17 .0) 4.0 (16.0) 4.7 (20.5)        0.001
LNG/EE 78.0 (14.0) 74.5 (12.0) 75.0 (11.5)        3.0  (14.0)      3.6  (17 .5)
  Procoagulatory factors 
  Factor II (%) 
NOMAC/E2 93.0 (15.0) 97 .0 (14.0) 95.0 (19.0)        1.0  (18.0)      0.9  (18.5) 0.50
LNG/EE 94.5 (15.0) 101.5 (14.0) 95.0 (20.0) 3.0 (19.5) 3.0 (22.7)
  Factor VIIa (U/l) 
NOMAC/E2 80.0 (41.5) 84.0 (44.0) 82.0 (47 .0) 7 .0 (46.9) 8.8 (63.3) 0.42
LNG/EE 71.0 (35.0) 91.5 (45.0) 86.0 (37 .5) 9.0 (30.0) 14.4 (42.0)
  Factor VIIc (%) 
NOMAC/E2 102.0 (30.5) 105.0 (36.0) 103.0 (28.0) 1.0 (33.0) 1.0 (33.3) 0.001
LNG/EE 101.0 (30.0) 98.5 (25.0) 94.5 (31.5)        13.0  (27 .5)      12.7  (24.1)
  Factor VIII (%) 
NOMAC/E2 87 .0 (45.0) 86.0 (45.0) 85.0 (45.0) 3.0 (47 .0) 4.8 (51.8) 0.38
LNG/EE 88.5 (42.0) 87 .0 (41.0) 95.5 (43.0) 6.0 (34.5) 6.8 (40.6)
  FEU, Fibrinogen equivalent units; ETP , endogenous thrombin potential; aPTT, activated partial thromboplastin time; 
APC, activated protein C; Factor VIIa, activated Factor VII; factor VIIc, coagulated activated Factor VII. 
        ∗  The Cochran-Mantel-Haenszel test adjusted for age class using standardised midranks, applied on the absolute 
changes from baseline to cycle 6. A   p  -value      0.05 indicates that the difference from baseline to cycle 6 (NOMAC/
E2 vs LNG/EE) was statistically signiﬁ  cant.     
      †   The   p  -value is not presented because   	   50% of subjects had D-dimer values below the lower limit of quantiﬁ  cation 
(LLOQ) of 0.22 mg/l FEU.         Effects of NOMAC/E2 on haemostasis and lipids    Ågren et al.
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  CRP and SHBG 
  Although CRP concentrations increased after treat-
ment in both groups, the increase from baseline was 
signiﬁ  cantly smaller with NOMAC/E2 (     67%) than 
with LNG/EE (     258%)  ( p        0.001; Table 3). Both 
COCs were associated with increases in SHBG con-
centrations, with a signiﬁ  cantly greater increase in the 
NOMAC/E2 group (44%) compared with the LNG/
EE group (22%) (  p        0.019; Table 3; Figure 2).     
  Contraceptive efﬁ  cacy and tolerability 
  No pregnancies occurred during the trial in either 
treatment group. NOMAC/E2 was generally well tol-
erated, with a similar AE proﬁ   le as LNG/EE. AEs 
reported with an incidence        5% (in any treatment 
group) in women who received either NOMAC/E2 
or LNG/EE, respectively, were upper respiratory tract 
infection (6 and 5 subjects), headache (3 and 7 subjects), 
acne (2 and 4 subjects), inﬂ   uenza (1 and 4 subjects), 
metrorrhagia (3 and 1 subject), and vaginal candidiasis 
(3 and 1 subject). One serious adverse event (SAE), 
worsening of a congenital mitral valve leak, was 
reported in the NOMAC/E2 group. The subject was 
withdrawn from the study. No SAEs were reported in 
the LNG/EE group. Eight women (four women in 
each group) discontinued treatment during the study 
because of an AE. In the NOMAC/E2 group, reasons 
for discontinuation due to an AE included depression 
and nausea; one subject experienced a combination 
of tachycardia, pain in the calf, and weakness in the 
limb. In the LNG/EE group, AEs that led to discon-
tinuation included decreased sexual desire, nausea, and 
headache.       
    DISCUSSION   
  This randomised study compared the effects of 
NOMAC/E2 administered in a 24-day regimen and 
LNG/EE in a 21-day regimen on metabolic indices. 
   
  Figure 2   Box whisker plots for NOMAC/E2 and LNG/EE of relative changes from baseline to end of cycle 6 in selected 
haemostatic and lipid parameters and SHBG. The edges of the boxes present the 25th and 75th sample percentiles 
(quartiles). The distance between these sample percentiles is the interquartile range. The vertical line in the box shows the 
median and the whiskers are drawn up to the smallest and largest value within 1.5-times the interquartile range. NOMAC, 
nomegestrol acetate/17  β  -oestradiol; LNG, levonorgestrel/ethinylestradiol; APCsr, activated protein C sensitivity ratio; ETP , 
endogenous thrombin potential; aPTT, activated partial thromboplastin time; HDL -C, high-density lipoprotein cholesterol; 
LDL -C, low-density lipoprotein cholesterol; SHBG, sex hormone-binding globulin.   Effects of NOMAC/E2 on haemostasis and lipids    Ågren et al.
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contraceptive efﬁ  cacy and safety since their introduc-
tion in 1960. However, epidemiological evidence 
linking COC use with an increased risk of cardio-
vascular morbidity, particularly of VTE, remains a 
cause for concern. Several factors have been associ-
ated with VTE risk in women taking EE-containing 
COCs, including the EE dose  20,21   and type of pro-
gestogen used  21  –  25  . Whether observed differences in 
VTE risk among COC formulations can be explained 
by confounding factors and biases in study design and 
After six cycles of treatment, NOMAC/E2 had 
minimal inﬂ  uence on parameters related to haemo-
stasis, lipids, and carbohydrate metabolism. Overall, 
NOMAC/E2 had less effect on these indices than the 
comparator LNG/EE. Both NOMAC/E2 and LNG/
EE were associated with moderate increases in SHBG 
and increases in CRP. Changes in CRP were particu-
larly marked with LNG/EE. 
  An estimated 100 million women worldwide use 
COCs  1  , which have demonstrated an excellent overall 
      Table 3    Comparison of the effects of nomegestrol acetate/17  β  -oestradiol (NOMAC/E2) and levonorgestrel/
ethinylestradiol (LNG/EE) on lipid indices, CRP , and SHBG (medians [interquartile ranges]).   
  Lipid indices 
  Treatment   Baseline   Cycle 3    Cycle 6 
  Change from 
baseline to 
cycle 6 
  % change 
from baseline 
to cycle 6    p-value  *   
  Total cholesterol (mmol/l) 
NOMAC/E2 4.33 (1.23) 4.22 (1.04) 4.35 (1.09) 0.08 (0.65) 1.3 (16.9) 0.69
LNG/EE 4.43 (1.01) 4.37 (0.91) 4.40 (1.14)        0.03  (0.75)      0.7  (15.8)
  HDL -C (mmol/l) 
NOMAC/E2 1.58 (0.41) 1.58 (0.44) 1.63 (0.44) 0.02 (0.32) 1.6 (21.0)        0.001
LNG/EE 1.66 (0.42) 1.47 (0.37) 1.35 (0.34)        0.23  (0.32)      13.1  (18.0)
  LDL -C (mmol/l) 
NOMAC/E2 2.28 (0.92) 2.07 (0.91) 2.15 (0.78)        0.02  (0.48)      0.5  (26.2) 0.046
LNG/EE 2.41 (0.81) 2.43 (0.98) 2.43 (1.09) 0.11 (0.52) 6.8 (20.1)
  Total triglycerides (mmol/l) 
NOMAC/E2 0.90 (0.32) 0.88 (0.47) 0.92 (0.41) 0.06 (0.29) 7 .5 (34.8) 0.008
LNG/EE 0.75 (0.32) 0.93 (0.49) 0.99 (0.48) 0.15 (0.44) 17 .0 (56.4)
  Lipoprotein (a) (g/l) 
NOMAC/E2 0.10 (0.15) 0.10 (0.16) 0.10 (0.19) 0.00 (0.03) 0.0 (20.3)        0.001
LNG/EE 0.11 (0.19) 0.10 (0.13) 0.10 (0.18)        0.02  (0.05)      14.0  (30.7)
  Apolipoprotein A1 (g/l) 
NOMAC/E2 1.59 (0.30) 1.66 (0.42) 1.73 (0.44) 0.20 (0.30) 12.1 (20.2) 0.006
LNG/EE 1.56 (0.32) 1.65 (0.35) 1.66 (0.30) 0.09 (0.26) 4.6 (17 .5)
  Apolipoprotein B (g/l) 
NOMAC/E2 0.61 (0.21) 0.60 (0.24) 0.62 (0.26) 0.03 (0.12) 4.6 (20.0)        0.001
LNG/EE 0.63 (0.16) 0.77 (0.27) 0.79 (0.28) 0.16 (0.21) 28.0 (32.0)
  CRP (mg/l) 
NOMAC/E2 0.40 (0.60) 0.60 (1.40) 0.70 (1.00) 0.20 (0.80) 66.7 (200.0)        0.001
LNG/EE 0.40 (1.30) 1.75 (3.00) 1.70 (2.85) 0.95 (2.20) 258.3 (495.5)
  SHBG (nmol/l) 
NOMAC/E2 65.5 (33.6) 96.3 (55.5) 107 .9 (57 .8) 33.8 (52.0) 44.1 (78.8) 0.019
LNG/EE 76.5 (40.6) 93.9 (47 .6) 98.3 (30.8) 15.3 (42.6) 22.4 (64.1)
  HDL -C, high-density lipoprotein cholesterol; LDL -C, low-density lipoprotein cholesterol; CRP , C-reactive protein; SHBG, 
sex hormone-binding globulin. 
        *  The Cochran-Mantel-Haenszel test adjusted for age class using standardised midranks, applied on the absolute 
changes from baseline to cycle 6. A   p  -value      0.05 indicates that the difference from baseline to cycle 6 (NOMAC/
E2 vs LNG/EE) was statistically signiﬁ  cant.         Effects of NOMAC/E2 on haemostasis and lipids    Ågren et al.
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methodology remains the subject of debate  5  . Reduc-
tions in the dose of EE (     50   μ  g) have resulted in a 
decreased incidence of VTE  21  , ischaemic stroke  25,26  , 
and myocardial infarction  25  . Further reduction of the 
EE dose to 20   μ  g may further decrease the VTE 
incidence (suggested in a case-control study  21  ), but 
the evidence for this is limited. Even very low doses 
of EE (i.e., 10   μ  g) have been shown to adversely 
affect haemostatic parameters  27  . 
  COC formulations containing oestrogen that are 
structurally similar or identical to endogenous E2 have 
been sought for several decades because they are 
expected to offer an improved safety proﬁ  le. A number 
of clinical studies have demonstrated that E2 and its 
derivative oestradiol valerate have less effect on hepatic 
protein synthesis than EE and have more favourable 
lipid and haemostatic proﬁ  les  27  –  29  . This is conﬁ  rmed 
by data from the present study, in that NOMAC/E2 
had less inﬂ  uence on indices of haemostasis, lipid and 
carbohydrate metabolism than LNG/EE (150   μ  g/30   μ  g), 
as well as by the results of a previous study, which 
showed that NOMAC/E2 induced smaller changes on 
coagulation and ﬁ   brinolysis markers relative to the 
lower-dosed COC LNG/EE 100   μ  g/20   μ  g  30  . The 
apparent improved safety proﬁ   le of E2-containing 
COCs needs to be conﬁ  rmed in clinical studies with 
VTE as endpoint. 
  COCs containing EE have been associated with 
pronounced APC resistance  31,32   as well as elevations in 
procoagulatory factors and reductions in anticoagula-
tory factors  33,34  . Reduced sensitivity for ETP-based 
APC has been claimed to be associated with VTE risk 
in men and women, even in the absence of the Factor 
V Leiden mutation  35,36  . In the current study,  NOMAC/
E2 resulted in changes in ETP-based APC sensitivity 
ratios that were substantially and signiﬁ  cantly smaller 
than ratios observed with LNG/EE. 
  Evidence suggests that the individual composition 
of different COCs, in terms of hormone dose and 
progestogen type, also inﬂ  uences their respective effects 
on lipids and lipoproteins  37,38  . Although the changes 
in lipoprotein metabolism induced by EE are complex, 
the net effect is generally considered favourable, primar-
ily due to increased HDL concentrations. Progestogens 
      Table 4    Comparison of the effects of nomegestrol acetate/17  β  -oestradiol (NOMAC/E2) and levonorgestrel/
ethinylestradiol (LNG/EE) on carbohydrate indices (medians [interquartile ranges]).   
  Carbohydrate indices 
  Treatment   Baseline   Cycle 3    Cycle 6 
  Change from 
baseline to 
cycle 6 
  % change from 
baseline to 
cycle 6    p-value  *   
  AUC    3     for glucose (hours       mmol/l) 
NOMAC/E2 15.73 (3.49) 15.95 (3.46) 15.31 (3.75) 0.79 (3.37) 6.1 (25.7) 0.002
LNG/EE 14.12 (3.26) 16.19 (4.58) 16.34 (4.71) 2.08 (3.16) 13.9 (24.5)
  Incremental AUC    3     for glucose (hours       mmol/l) 
NOMAC/E2 1.15 (3.35) 1.27 (3.29) 1.25 (2.93) 0.61 (3.02) 25.4 (207 .6)        0.001
LNG/EE 0.64 (3.06) 2.95 (4.05) 2.87 (4.03) 2.07 (3.50) 56.5 (273.0)
  AUC    3     for insulin (hours       mmol/l) 
NOMAC/E2 585.6 (304.0) 654.5 (488.3) 620.3 (357 .1)        4.1  (240.6)      0.9  (33.1)      0.001
LNG/EE 540.6 (218.7) 702.6 (375.0) 704.7 (356.0) 177 .9 (275.2) 26.4 (53.7)
  Incremental AUC    3     for insulin (hours       mmol/l) 
NOMAC/E2 447 .6 (302.3) 496.1 (387 .3) 481.1 (270.5)        29.5  (241.3)      6.1  (57 .1) 0.002
LNG/EE 432.1 (179.2) 592.8 (348.5) 588.3 (284.7) 147 .9 (299.8) 35.9 (69.5)
  HbA    1c     (%) 
NOMAC/E2 5.35 (0.35) 5.40 (0.30) 5.30 (0.30) 0.00 (0.20) 0.0 (3.7) 0.37
LNG/EE 5.30 (0.20) 5.40 (0.20) 5.30 (0.30) 0.00 (0.20) 0.0 (3.7)
  AUC  3  , area under the curve over three hours; HbA  1c  , haemoglobin type A  1c  . 
        *  The Cochran-Mantel-Haenszel test adjusted for age class using standardised midranks, applied on the absolute 
changes from baseline to cycle 6. A   p  -value      0.05 indicates that the difference from baseline to cycle 6 (NOMAC/
E2 vs LNG/EE) was statistically signiﬁ  cant.         Effects of NOMAC/E2 on haemostasis and lipids    Ågren et al.
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with androgenic properties may reverse the lipid ben-
eﬁ  ts of oestrogen, whereas natural progesterone, pro-
gesterone-like derivatives and DRSP may be more 
likely to preserve these beneﬁ  ts  39  . In the present study, 
NOMAC/E2 did not induce any meaningful changes 
in the lipid proﬁ  le, whereas women receiving LNG/
EE demonstrated a reduction in HDL-C and an eleva-
tion in LDL-C and total triglycerides. These results are 
consistent with those observed in previous studies of 
LNG/EE  40  –  42  . 
  Hormonal contraceptives (including COCs) have 
been associated with subclinical disturbances in car-
bohydrate metabolism, including impaired glucose 
tolerance and insulin resistance  43   that may increase 
the risk of type 2 diabetes and vascular disease. Stud-
ies evaluating the effects of oestrogen on carbohydrate 
metabolism have reported contradictory ﬁ  ndings  44  –  50  . 
The androgenic properties of the proge  stogens used 
in COCs may inﬂ  uence responses to glucose toler-
ance tests; non-androgenic progestogens appear to 
exert a neutral effect on carbohydrate metabolism  51  . 
In the present study, negligible changes in glucose 
and insulin parameters were observed in women tak-
ing NOMAC/E2, whereas signiﬁ   cant increases in 
insulin and glucose AUC  3   were found in women 
taking LNG/EE. The increases associated with 
LNG/EE are in line with those observed in 
previous studies  40,42  , but it is doubtful whether they 
are clinically meaningful in terms of predicting 
greater risk. 
  The role of inﬂ  ammation in the pathogenesis of 
cardiovascular disease (CVD) has been increasingly 
recognised in recent years, and inﬂ  ammation markers 
such as the non-speciﬁ  c acute-phase protein CRP 
have been identiﬁ   ed as useful predictors of CVD 
risk  52  . In clinical studies, elevations in CRP levels 
have been observed with the use of various COC 
formulations  53  –  55  . Both NOMAC/E2 and LNG/EE 
increased CRP levels in this randomised metabolic 
study, with a signiﬁ  cantly greater increase seen with 
LNG/EE. Whereas the median CRP level observed 
in the NOMAC/E2 group at cycle 6 (0.70 mg/l) 
remained well below the threshold indicating increased 
cardiovascular risk (     2  mg/l) 56  , the median CRP 
level in the LNG/EE group at cycle 6 (1.70 mg/l) 
approached this threshold. 
  SHBG is a carrier protein synthesised in hepato-
cytes; its synthesis has been shown to be highly sensi-
tive to oestrogens and androgens  57  . EE administered 
orally markedly increases SHBG levels in a dose-
dependent fashion, whereas progestogens, due to their 
androgenic properties, decrease these levels to a vary-
ing extent depending on the steroid dose and type. 
The net effect of a COC formulation on SHBG thus 
appears to reﬂ  ect the balance between oestrogenic and 
androgenic activity  57  . In this study, NOMAC/E2 
induced an approximate 44% increase from baseline in 
SHBG, a change that was signiﬁ  cantly greater than the 
22% rise induced by LNG/EE. However, compared 
with other COCs, where increases in SHBG vary from 
150% for COCs containing norgestimate to 400% for 
COCs containing cyproterone acetate, the SHBG 
increases observed in this study were small  57  . The rise 
in SHBG induced by LNG/EE is most likely the result 
of the increase due to EE and the decrease due to 
LNG, a progestogen with residual androgenicity. The 
rise in SHBG induced by NOMAC/E2 is most likely 
only due to the oestrogen component of this combi-
nation because NOMAC is a non-androgenic 
progestogen. 
  This is one of the ﬁ  rst studies reporting the effect 
of a COC that contains E2 instead of EE on several 
metabolic indices. The VTE risk and metabolic effects 
of the comparator COC LNG/EE (150   μ  g/30   μ  g) 
have been well established, and it is therefore an appro-
priate comparator. The inﬂ  uence of NOMAC/E2 on 
haemostatic indices has also been studied in compari-
son to the lower-dosed COC containing LNG/EE 
(100   μ  g/20   μ  g), with essentially similar results  30  . 
Although direct comparisons between NOMAC/E2 
and COCs containing progestogens other than LNG 
are not yet available, it is likely that these COCs are 
associated with greater changes in these indices than 
NOMAC/E2, in view of their generally more pro-
nounced effects in comparison to LNG/EE  58,59  . 
  The main limitation of this study is the use of sur-
rogate endpoints for metabolic indices. In addition, 
none of the haemostatic indices measured in this study 
have been established as deﬁ  nitive markers of throm-
bosis, and the clinical relevance of the differences 
found in this study can only be determined by per-
forming large, clinical studies with VTE as endpoint. 
The same holds true for other indices, including lipids 
and carbohydrate metabolism. 
  In summary, NOMAC/E2 had minimal inﬂ  uence 
on haemostatic, lipid and carbohydrate metabolism 
indices and caused less change in these parameters than 
LNG/EE. Large clinical studies will be needed to Effects of NOMAC/E2 on haemostasis and lipids    Ågren et al.
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